BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 10052897)

  • 1. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
    Johnson EM; Szekely A; Warnock DW
    J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN;
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens.
    Johnson EM; Szekely A; Warnock DW
    Antimicrob Agents Chemother; 1999 May; 43(5):1260-3. PubMed ID: 10223947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.
    Wildfeuer A; Seidl HP; Paule I; Haberreiter A
    Mycoses; 1998; 41(7-8):309-19. PubMed ID: 9861837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
    Espinel-Ingroff A; Johnson E; Hockey H; Troke P
    J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
    Marco F; Pfaller MA; Messer SA; Jones RN
    Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.
    Espinel-Ingroff A; Boyle K; Sheehan DJ
    Mycopathologia; 2001; 150(3):101-15. PubMed ID: 11469757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study.
    Morace G; Drago M; Scaltrito MM; Conti S; Fanti F; Polonelli L;
    J Chemother; 2007 Oct; 19(5):508-13. PubMed ID: 18073149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.
    Espinel-Ingroff A
    J Clin Microbiol; 1998 Jan; 36(1):198-202. PubMed ID: 9431946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum.
    Li RK; Ciblak MA; Nordoff N; Pasarell L; Warnock DW; McGinnis MR
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1734-6. PubMed ID: 10817743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species.
    Arikan S; Lozano-Chiu M; Paetznick V; Nangia S; Rex JH
    J Clin Microbiol; 1999 Dec; 37(12):3946-51. PubMed ID: 10565912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B.
    McGinnis MR; Nordoff N; Li RK; Pasarell L; Warnock DW
    Med Mycol; 2001 Aug; 39(4):369-71. PubMed ID: 11556767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
    J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.
    González GM; Fothergill AW; Sutton DA; Rinaldi MG; Loebenberg D
    Med Mycol; 2005 May; 43(3):281-4. PubMed ID: 16010855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
    Lewis RE; Wiederhold NP; Klepser ME
    Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B.
    Oakley KL; Moore CB; Denning DW
    J Antimicrob Chemother; 1998 Jul; 42(1):91-4. PubMed ID: 9700534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.
    Radford SA; Johnson EM; Warnock DW
    Antimicrob Agents Chemother; 1997 Apr; 41(4):841-3. PubMed ID: 9087501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.